AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28810814 — intervention group
Group type: EXPERIMENTAL
Intervention: Vocational advice (VA) service
Number of subjects: 34
Study 28810814 — intervention group
Group type: EXPERIMENTAL
Intervention: Early vocational intervention
Number of subjects: 34
Study 28510740 — intervention group
Group type: EXPERIMENTAL
Intervention: PROP (donor and recipient propofol)
Number of subjects: 57
Study 28510740 — intervention group
Group type: EXPERIMENTAL
Intervention: SEVO (donor and recipient sevoflurane)
Number of subjects: 57
Study 28510740 — intervention group
Group type: EXPERIMENTAL
Intervention: PROSE (donor propofol and recipient sevoflurane)
Number of subjects: 57
Study 25972158 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral dexamethasone 40 mg for days 1 to 4, oral cyclosporine 2.5 to 3 mg/kg daily for days 1 to 28, intravenous low-dose rituximab 100 mg for days 7, 14, 21, and 28.
Number of subjects: 20
Study 23305576 — intervention group
Group type: EXPERIMENTAL
Intervention: HTK solution (16 patients)
Number of subjects: 32
Study 23305576 — intervention group
Group type: COMPARATOR
Intervention: Conventional crystalloid cardioplegia (KK group, 16 patients)
Number of subjects: 32
Study 20721895 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided self-help (GSH) treatment
Number of subjects: 87
Study 19950775 — intervention group
Group type: EXPERIMENTAL
Intervention: PPI with Ecabet Sodium (ES)
Number of subjects: 56
Study 19950775 — intervention group
Group type: COMPARATOR
Intervention: PPI alone
Number of subjects: 56
Study 17093107 — intervention group
Group type: EXPERIMENTAL
Intervention: Earnings supplement (qualifying by working full-time)
Number of subjects: 0
Study 14986257 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 100
Study 14986257 — intervention group
Group type: COMPARATOR
Intervention: No Vitamin A supplementation
Number of subjects: 100
Study 14986257 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamins B-complex, C, and E
Number of subjects: 100
Study 11717613 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak E‐wave velocity >1.2 m/s suggesting severe MR in patients with normal EF
Number of subjects: 135
Study 11717613 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak E‐wave velocity >1.2 m/s suggesting severe MR in patients with low EF
Number of subjects: 135
Study 11717613 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak E‐wave velocity and E/A ratio
Number of subjects: 135
Study 11717613 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of Peak E‐wave velocity with regurgitant fraction (RF)
Number of subjects: 135
Study 11717613 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of Peak E‐wave velocity with ejection fraction (EF)
Number of subjects: 135
Study 11717613 — intervention group
Group type: EXPERIMENTAL
Intervention: E‐wave deceleration, LV isovolumetric relaxation, and contraction time
Number of subjects: 135
Study 9203756 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient geriatric evaluation and management (GEM)
Number of subjects: 0
Study 9203756 — intervention group
Group type: COMPARATOR
Intervention: Usual outpatient primary care (UPC)
Number of subjects: 0
Study 8070258 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiload 375
Number of subjects: 3655
Study 8070258 — intervention group
Group type: COMPARATOR
Intervention: TCu380A
Number of subjects: 3655
Study 3204249 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalmefene, 20 mg
Number of subjects: 10
Study 3204249 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 29091082 — intervention group
Group type: EXPERIMENTAL
Intervention: Linaclotide 72 μg
Number of subjects: 1223
Study 29091082 — intervention group
Group type: EXPERIMENTAL
Intervention: Linaclotide 145 μg
Number of subjects: 1223
Study 29091082 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1223
Study 28417527 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin (10 mg)
Number of subjects: 33
Study 28417527 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 26227018 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter removal on postoperative day 2 (group 1)
Number of subjects: 113
Study 26227018 — intervention group
Group type: COMPARATOR
Intervention: Catheter removal on postoperative day 4 (group 2)
Number of subjects: 113
Study 26227018 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter removal on postoperative day 2 (group 1) with acute urinary retention (AUR)
Number of subjects: 113
Study 26227018 — intervention group
Group type: COMPARATOR
Intervention: Catheter removal on postoperative day 4 (group 2) with acute urinary retention (AUR)
Number of subjects: 113
Study 23618489 — intervention group
Group type: COMPARATOR
Intervention: Daily Iron and Folic Acid Supplementation
Number of subjects: 120
Study 23618489 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly Iron and Folic Acid Supplementation
Number of subjects: 120
Study 21948069 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (4 mg/kg loading dose administered intravenously)
Number of subjects: 52
Study 18322858 — intervention group
Group type: EXPERIMENTAL
Intervention: modafinil 400 mg
Number of subjects: 54
Study 18322858 — intervention group
Group type: EXPERIMENTAL
Intervention: dextroamphetamine 20 mg
Number of subjects: 54
Study 18322858 — intervention group
Group type: EXPERIMENTAL
Intervention: caffeine 600 mg
Number of subjects: 54
Study 18322858 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 54
Study 17159011 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation (600 IU [alpha‐tocopherol acetate], on alternate days)
Number of subjects: 6377
Study 17159011 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6377
Study 14616278 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisection-morcellation
Number of subjects: 30
Study 14616278 — intervention group
Group type: COMPARATOR
Intervention: Myometrial coring
Number of subjects: 30
Study 10795647 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide aqueous nasal spray (256 microg daily)
Number of subjects: 314
Study 10795647 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate nasal spray (200 microg daily)
Number of subjects: 314
Study 10795647 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 314
Study 8650941 — intervention group
Group type: EXPERIMENTAL
Intervention: Wobenzym
Number of subjects: 55
Study 8650941 — intervention group
Group type: COMPARATOR
Intervention: Diuretics
Number of subjects: 55
Study 1450046 — intervention group
Group type: EXPERIMENTAL
Intervention: rIFN‐alpha 2a (3 MU/m2 s.c. three times weekly for 6 months)
Number of subjects: 23
Study 1450046 — intervention group
Group type: EXPERIMENTAL
Intervention: rIFN‐alpha 2a (3 MU/m2 five days/week for an additional 6 months after chemotherapy)
Number of subjects: 23
Study 1450046 — intervention group
Group type: COMPARATOR
Intervention: Combination of rIFN‐alpha 2a, streptozocin (2 g), and doxorubicin (40 mg/m2)
Number of subjects: 23
Study 1450046 — intervention group
Group type: COMPARATOR
Intervention: Combination treatment
Number of subjects: 23
Study 6483935 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam 0.2 mg/kg (oral administration)
Number of subjects: 50
Study 6483935 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam 0.2 mg/kg (intravenous administration)
Number of subjects: 50
Study 6483935 — intervention group
Group type: COMPARATOR
Intervention: Placebo (oral administration)
Number of subjects: 50
Study 30772154 — intervention group
Group type: EXPERIMENTAL
Intervention: Di(2-propylheptyl) phthalate (DPHP) exposure measurement
Number of subjects: 180
Study 30772154 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary metabolite concentrations of DPHP
Number of subjects: 180
Study 30772154 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporal trends of DPHP exposure
Number of subjects: 180
Study 29557889 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual resistance-based neck strengthening (n = 13)
Number of subjects: 17
Study 29557889 — intervention group
Group type: COMPARATOR
Intervention: Control resistance exercise (n = 4)
Number of subjects: 17
Study 26605836 — intervention group
Group type: EXPERIMENTAL
Intervention: Aflibercept (2.0 mg, 0.05 mL intravitreous injections)
Number of subjects: 660
Study 26605836 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab (1.25 mg, 0.05 mL intravitreous injections)
Number of subjects: 660
Study 26605836 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab (0.3 mg, 0.05 mL intravitreous injections)
Number of subjects: 660
Study 26605836 — intervention group
Group type: EXPERIMENTAL
Intervention: Aflibercept (2.0 mg)
Number of subjects: 660
Study 26605836 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab (1.25 mg)
Number of subjects: 660
Study 26605836 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab (0.3 mg)
Number of subjects: 660
Study 26605836 — intervention group
Group type: COMPARATOR
Intervention: Aflibercept vs Bevacizumab
Number of subjects: 660
Study 26605836 — intervention group
Group type: COMPARATOR
Intervention: Ranibizumab vs Bevacizumab
Number of subjects: 660
Study 26605836 — intervention group
Group type: EXPERIMENTAL
Intervention: Aflibercept vs Ranibizumab
Number of subjects: 660
Study 24461903 — intervention group
Group type: EXPERIMENTAL
Intervention: Losmapimod 2.5 mg
Number of subjects: 602
Study 24461903 — intervention group
Group type: EXPERIMENTAL
Intervention: Losmapimod 7.5 mg
Number of subjects: 602
Study 24461903 — intervention group
Group type: EXPERIMENTAL
Intervention: Losmapimod 15 mg
Number of subjects: 602
Study 24461903 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 602
Study 22538854 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.1 × 10(11) platelets/m(2) per transfusion
Number of subjects: 1242
Study 22538854 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.2 × 10(11) platelets/m(2) per transfusion
Number of subjects: 1242
Study 22538854 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.4 × 10(11) platelets/m(2) per transfusion
Number of subjects: 1242
Study 22538854 — intervention group
Group type: COMPARATOR
Intervention: Control group (adults)
Number of subjects: 1242
Study 22538854 — intervention group
Group type: EXPERIMENTAL
Intervention: All pediatric groups
Number of subjects: 1242
Study 20585757 — intervention group
Group type: EXPERIMENTAL
Intervention: UretexTO
Number of subjects: 70
Study 20585757 — intervention group
Group type: COMPARATOR
Intervention: PelviLaceTO
Number of subjects: 70
Study 17580253 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole
Number of subjects: 299
Study 17580253 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 299
Study 15642547 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal balloon occlusion device
Number of subjects: 801
Study 15642547 — intervention group
Group type: COMPARATOR
Intervention: No distal balloon occlusion device (control)
Number of subjects: 801
Study 11972594 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT)
Number of subjects: 56
Study 11972594 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 9654837 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg of proglumide with one-half analgesic dose
Number of subjects: 60
Study 9654837 — intervention group
Group type: COMPARATOR
Intervention: Placebo with full analgesic dose
Number of subjects: 60
Study 8605516 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate-electrolyte (CE) solution (6.9% providing 1.0 g CHO.kg body weight‐1)
Number of subjects: 16
Study 8605516 — intervention group
Group type: COMPARATOR
Intervention: Placebo solution (control group)
Number of subjects: 16
Study 2668259 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg/day
Number of subjects: 40
Study 2668259 — intervention group
Group type: COMPARATOR
Intervention: Trazodone
Number of subjects: 40
Study 29240021 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic seizure therapy (MST)
Number of subjects: 24
Study 29240021 — intervention group
Group type: COMPARATOR
Intervention: Electroconvulsive shock (ECS)
Number of subjects: 24
Study 29240021 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing electrical dosage
Number of subjects: 24
Study 29240021 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing MST dosage
Number of subjects: 24
Study 28676038 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sildenafil for 16 weeks
Number of subjects: 48
Study 28676038 — intervention group
Group type: COMPARATOR
Intervention: Oral sildenafil
Number of subjects: 48
Study 26260553 — intervention group
Group type: EXPERIMENTAL
Intervention: REM Desensitization
Number of subjects: 33
Study 26260553 — intervention group
Group type: EXPERIMENTAL
Intervention: EMDR
Number of subjects: 33
Study 23307149 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocytoscopy
Number of subjects: 170
Study 23307149 — intervention group
Group type: COMPARATOR
Intervention: Standard biopsy
Number of subjects: 170
Study 21586432 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 M sucrose (intervention)
Number of subjects: 201
Study 21586432 — intervention group
Group type: COMPARATOR
Intervention: 0.1 M sucrose (control)
Number of subjects: 201
Study 21586432 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined fresh and frozen cycles
Number of subjects: 201
Study 19632969 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 weeks of immediate-program-access as an add-on to treatment-as-usual (N = 320)
Number of subjects: 396
Study 19632969 — intervention group
Group type: COMPARATOR
Intervention: 9-week delayed-access plus treatment-as-usual (N = 76)
Number of subjects: 396
Study 16861168 — intervention group
Group type: EXPERIMENTAL
Intervention: Qi therapy without touching (QTN)
Number of subjects: 24
Study 16861168 — intervention group
Group type: EXPERIMENTAL
Intervention: Qi therapy with touching (QTT)
Number of subjects: 24
Study 12638397 — intervention group
Group type: EXPERIMENTAL
Intervention: Wood creosote 45 mg
Number of subjects: 60
Study 12638397 — intervention group
Group type: EXPERIMENTAL
Intervention: Wood creosote 90 mg
Number of subjects: 60
Study 12638397 — intervention group
Group type: EXPERIMENTAL
Intervention: Wood creosote 135 mg
Number of subjects: 60
Study 12638397 — intervention group
Group type: EXPERIMENTAL
Intervention: Wood creosote 180 mg
Number of subjects: 60
Study 12638397 — intervention group
Group type: EXPERIMENTAL
Intervention: Wood creosote 225 mg
Number of subjects: 60
Study 12638397 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 10713659 — intervention group
Group type: EXPERIMENTAL
Intervention: CHOP plus high-dose tamoxifen (Group II)
Number of subjects: 98
Study 10713659 — intervention group
Group type: COMPARATOR
Intervention: CHOP only (Group I)
Number of subjects: 98
Study 10713659 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 98
Study 8874676 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous nerve stimulation (TNS) applied to hand
Number of subjects: 10
Study 8874676 — intervention group
Group type: COMPARATOR
Intervention: Transcutaneous nerve stimulation (TNS) applied to foot (placebo)
Number of subjects: 10
Study 1373949 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcipotriol
Number of subjects: 20
Study 1373949 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone valerate
Number of subjects: 20
Study 3549879 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol decanoate
Number of subjects: 19
Study 3549879 — intervention group
Group type: COMPARATOR
Intervention: Fluphenazine decanoate
Number of subjects: 19
Study 29505379 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent mentors
Number of subjects: 155
Study 27138020 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous suction drain (SD)
Number of subjects: 118
Study 27138020 — intervention group
Group type: COMPARATOR
Intervention: No subcutaneous suction drain (no SD)
Number of subjects: 118
Study 24863954 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-directed discharge letter (PADDLE)
Number of subjects: 67
Study 24863954 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 67
Study 22659998 — intervention group
Group type: EXPERIMENTAL
Intervention: Malnutrition care plan (MCP) initiated immediately upon identification of malnutrition
Number of subjects: 143
Study 22659998 — intervention group
Group type: COMPARATOR
Intervention: No immediate MCP; only commenced if referred by clinical staff
Number of subjects: 143
Study 22659998 — intervention group
Group type: EXPERIMENTAL
Intervention: Malnutrition screening using the Mini Nutritional Assessment (MNA) tool
Number of subjects: 143
Study 22659998 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 143
Study 20570824 — intervention group
Group type: EXPERIMENTAL
Intervention: Short Alcohol Withdrawal Scale (SAWS)
Number of subjects: 122
Study 18634770 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 48
Study 18634770 — intervention group
Group type: COMPARATOR
Intervention: Bare metal stent (BMS)
Number of subjects: 48
Study 15714929 — intervention group
Group type: EXPERIMENTAL
Intervention: Involved field (IF) radiation
Number of subjects: 603
Study 15714929 — intervention group
Group type: COMPARATOR
Intervention: Extended field (EF) radiation
Number of subjects: 603
Study 15714929 — intervention group
Group type: COMPARATOR
Intervention: Total nodal irradiation (TNI)
Number of subjects: 603
Study 12297203 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine-enriched enteral diet
Number of subjects: 84
Study 12297203 — intervention group
Group type: COMPARATOR
Intervention: Control diet without glutamine
Number of subjects: 84
Study 10358788 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ketamine 2 mg kg‐1 hr‐1 and fentanyl 5 micrograms kg‐1 hr‐1 for the first 60 min and 3 micrograms kg‐1 hr‐1 for the next 90 min, and droperidol 0.1 mg kg‐1 (Group A)
Number of subjects: 40
Study 10358788 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ketamine 2 mg kg‐1 hr‐1, droperidol 0.1 mg kg‐1 and fentanyl 50‐100 micrograms in a bolus intermittently as needed (Group B)
Number of subjects: 40
Study 7579383 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential IL-3 and GM-CSF (schedule B)
Number of subjects: 93
Study 7579383 — intervention group
Group type: COMPARATOR
Intervention: Concurrent IL-3 and GM-CSF
Number of subjects: 93
Study 7579383 — intervention group
Group type: COMPARATOR
Intervention: IL-3 alone
Number of subjects: 93
Study 7579383 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 micrograms/kg IL-3
Number of subjects: 93
Study 1979272 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg dimetindene maleate
Number of subjects: 8
Study 1979272 — intervention group
Group type: COMPARATOR
Intervention: Sodium chloride solution (placebo)
Number of subjects: 8
Study 6767576 — intervention group
Group type: EXPERIMENTAL
Intervention: Brompheniramine maleate (antihistamine)
Number of subjects: 206
Study 6767576 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 206
Study 31035472 — intervention group
Group type: COMPARATOR
Intervention: Whole Avocado (WA)
Number of subjects: 31
Study 31035472 — intervention group
Group type: COMPARATOR
Intervention: Half Avocado (HA)
Number of subjects: 31
Study 31035472 — intervention group
Group type: COMPARATOR
Intervention: Low-Fat Control Meal (CON)
Number of subjects: 31
Study 28423931 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced walking program (incentives, feedback, competitive challenges, monthly wellness workshops)
Number of subjects: 474
Study 28423931 — intervention group
Group type: COMPARATOR
Intervention: Standard walking program
Number of subjects: 474
Study 28423931 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in average daily steps
Number of subjects: 474
Study 25470623 — intervention group
Group type: EXPERIMENTAL
Intervention: Dominant tinnitus pitch
Number of subjects: 129
Study 25470623 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinnitus pitch
Number of subjects: 129
Study 22302614 — intervention group
Group type: EXPERIMENTAL
Intervention: GeniVida™ bone blend (GBB) - genistein (30 mg/day), vitamin D3 (800 IU/day), vitamin K1 (150 μg/day), polyunsaturated fatty acids (1 g/day)
Number of subjects: 70
Study 22302614 — intervention group
Group type: COMPARATOR
Intervention: Calcium only (placebo)
Number of subjects: 70
Study 21462082 — intervention group
Group type: COMPARATOR
Intervention: Selenium-enriched yeast (247 μg/day for 9 months)
Number of subjects: 336
Study 21462082 — intervention group
Group type: EXPERIMENTAL
Intervention: Free-living adults
Number of subjects: 336
Study 18282776 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) replacement therapy, starting dose 0.003 mg/kg/day for 8 weeks, then adjusted based on serum IGF-I levels
Number of subjects: 71
Study 18282776 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) replacement therapy
Number of subjects: 71
Study 16433867 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivabradine (30 mg)
Number of subjects: 9
Study 16433867 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (40 mg)
Number of subjects: 9
Study 15569238 — intervention group
Group type: COMPARATOR
Intervention: HPA‐15 gene frequencies in Caucasians (0.53/0.47), African Brazilians (0.57/0.43), Orientals (0.57/0.43), and Brazilian blood donors (0.52/0.48)
Number of subjects: 276
Study 15569238 — intervention group
Group type: EXPERIMENTAL
Intervention: HPA‐15 gene frequencies in Xikrin Indians (0.78/0.22)
Number of subjects: 276
Study 15569238 — intervention group
Group type: EXPERIMENTAL
Intervention: HPA‐15 genotype frequencies in Gaviões Indians
Number of subjects: 276
Study 11061579 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerivastatin 0.8 mg with itraconazole 200 mg
Number of subjects: 18
Study 11061579 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg with itraconazole 200 mg
Number of subjects: 18
Study 11061579 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg with itraconazole 200 mg
Number of subjects: 18
Study 9315425 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Number of subjects: 299
Study 9315425 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 299
Study 8482184 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol (800 micrograms)
Number of subjects: 8
Study 8482184 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol (400 micrograms)
Number of subjects: 8